Cargando…

A “two-hit” (chemo)therapy to improve checkpoint inhibition in cancer

Detalles Bibliográficos
Autores principales:	Falvo, Paolo, Orecchioni, Stefania, Raveane, Alessandro, Mitola, Giulia, Bertolini, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2021
Materias:	Research Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8115984/ https://www.ncbi.nlm.nih.gov/pubmed/33997109 http://dx.doi.org/10.18632/oncoscience.533

Ejemplares similares

A single-cell transcriptomic landscape of innate and adaptive intratumoral immunity in triple negative breast cancer during chemo- and immunotherapies
por: Carpen, Laura, et al.
Publicado: (2022)

Vinorelbine and Intermittent Cyclophosphamide Sensitize an Aggressive Myc-Driven B-Cell Lymphoma to Anti-PD-1 by an Immunological Memory Effective against Tumor Re-Challenge
por: Orecchioni, Stefania, et al.
Publicado: (2023)

New Insight to Overcome Tumor Resistance: An Overview from Cellular to Clinical Therapies
por: Mitola, Giulia, et al.
Publicado: (2021)

The Dual Role of Innate Lymphoid and Natural Killer Cells in Cancer. from Phenotype to Single-Cell Transcriptomics, Functions and Clinical Uses
por: Roma, Stefania, et al.
Publicado: (2021)

Metformin sensitizes leukemic cells to cytotoxic lymphocytes by increasing expression of intercellular adhesion molecule-1 (ICAM-1)
por: Allende-Vega, Nerea, et al.
Publicado: (2022)

The metabolism of cells regulates their sensitivity to NK cells depending on p53 status
por: Belkahla, Sana, et al.
Publicado: (2022)

Eye: The Hard-hit Victim of COVID-19 Pandemic
por: Gaur, Aman, et al.
Publicado: (2022)

Dermatological Autoimmune Considerations of Immune Checkpoint Therapy
por: Fane, Lauren S., et al.
Publicado: (2022)

Women at medical conferences 2016 – still hitting their head at the glass ceiling
por: Amrein, Karin, et al.
Publicado: (2017)

Chemo-immunotherapy for Older Patients with Chronic Lymphocytic Leukemia – Time to Retire?
por: Scarfò, Lydia, et al.
Publicado: (2019)

Chemo-immunotherapy for Older Patients with Chronic Lymphocytic Leukemia – Passé Yet?
por: Danilov, Alexey V., et al.
Publicado: (2019)

Vinorelbine, cyclophosphamide and 5-FU effects on the circulating and intratumoural landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma
por: Orecchioni, Stefania, et al.
Publicado: (2018)

Chronically denervated distal nerve stump inhibits peripheral nerve regeneration
por: Ronchi, Giulia, et al.
Publicado: (2017)

Envisioning health equity for American Indian/Alaska Natives: a unique HIT opportunity
por: Cullen, Theresa, et al.
Publicado: (2019)

Biomarkers in renal cell carcinoma: Towards a more selective immune checkpoint inhibition
por: Sarkis, J., et al.
Publicado: (2021)

Cellular and Molecular Players in the Interplay between Adipose Tissue and Breast Cancer
por: Reggiani, Francesca, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors and Mismatch Repair Status in Advanced Endometrial Cancer: Elective Affinities
por: Rizzo, Alessandro
Publicado: (2022)

Neoadjuvant checkpoint inhibition in non-small cell lung cancer: Is earlier unquestionably better than later?
por: Olivier, Timothée, et al.
Publicado: (2022)

Checkpoint blockade therapy for functioning pituitary adenomas
por: Lorrey, Selena J., et al.
Publicado: (2020)

The two-hit theory hits 50
por: Chernoff, Jonathan
Publicado: (2021)

Potential tactics with vitamin D and certain phytochemicals for enhancing the effectiveness of immune-checkpoint blockade therapies
por: Tsuji, Ai, et al.
Publicado: (2023)

Is serine racemase (SRR) a second hit target for LRRK2-G2019S induced Parkinson’s disease?
por: Nickels, Sarah Louise, et al.
Publicado: (2020)

Targeting Protein Neddylation to Inactivate Cullin-RING Ligases by Gossypol: A Lucky Hit or a New Start?
por: Yu, Qing, et al.
Publicado: (2021)

An Anti-Checkpoint Activity for Rif1
por: Harari, Yaniv, et al.
Publicado: (2011)

Immune Checkpoint Inhibitor-related Endocrinopathies
por: Lu, Difei, et al.
Publicado: (2022)

Hallmarks of Resistance to Immune-Checkpoint Inhibitors
por: Karasarides, Maria, et al.
Publicado: (2022)

Plant TDP1 (Tyrosyl-DNA Phosphodiesterase 1): A Phylogenetic Perspective and Gene Expression Data Mining
por: Mutti, Giacomo, et al.
Publicado: (2020)

Enhanced Vascular Contractility Following Secondhand Smoke Exposure: A Pathological “Double-hit” to Critical Smooth Muscle Ion Channels
por: Klug, Nicholas R, et al.
Publicado: (2021)

The two "hit" and multiple "hit" theories of carcinogenesis.
por: Ashley, D. J.
Publicado: (1969)

Managing cardiotoxicity associated with immune checkpoint inhibitors
por: Upadhrasta, Sireesha, et al.
Publicado: (2019)

HSP90 as an emerging barrier to immune checkpoint blockade therapy
por: Tang, Daolin, et al.
Publicado: (2022)

Hit Discovery for Public Target Programs in the European Lead Factory: Experiences and Output from Assay Development and Ultra-High-Throughput Screening
por: Honarnejad, Saman, et al.
Publicado: (2020)

“Hit‐and‐Run” leaves its mark: Catalyst transcription factors and chromatin modification
por: Varala, Kranthi, et al.
Publicado: (2015)

The presence of wild type p53 in hematological cancers improves the efficacy of combinational therapy targeting metabolism
por: Allende-Vega, Nerea, et al.
Publicado: (2015)

Immune Checkpoint Inhibitor Therapy for Orbital and Ocular Adnexal Squamous Cell Carcinomas: International Society of Ocular Oncology President's Lecture, 2022
por: Esmaeli, Bita
Publicado: (2023)

Immune checkpoint molecules: “new” kids on the block of skin photoimmunology
por: Wang, Wei, et al.
Publicado: (2019)

A Combinatorial Investigation of the Response to Anti-angiogenic Therapy in Breast Cancer: New Strategies for Patient Selection and Opportunities for Reconsidering Anti-VEGF, Anti-PI3K and Checkpoint Inhibition
por: Labanca, Valentina, et al.
Publicado: (2016)

The Dysbiosis and Inter-Kingdom Synergy Model in Oropharyngeal Candidiasis, a New Perspective in Pathogenesis
por: Bertolini, Martinna, et al.
Publicado: (2019)

The future of immune checkpoint combinations with tumor-targeted small molecule drugs
por: Sceneay, Jaclyn, et al.
Publicado: (2021)

Basics for Improved Use of Phages for Therapy
por: Serwer, Philip, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_45df4tai9alegdq573e6p54o26